Aspivix, a Swiss medical device innovator dedicated to transforming women’s health, is excited to announce its latest funding round, securing an undisclosed amount of capital to accelerate the development and global rollout of its groundbreaking technologies. At the heart of this announcement is Carevix™, the world’s first suction cervical stabilizer that is setting a new standard in gynecological care. Clinically proven to reduce pain by up to 73% and bleeding by up to 83% during transcervical procedures such as IUD insertions, hysteroscopies, cervical biopsies, and fertility treatments, Carevix™ marks a transformative shift away from the century-old single-tooth tenaculum that has long dominated the field without consideration for patient comfort.
This new infusion of investment will be strategically deployed to scale research and development initiatives, enhance production capabilities, and expand market penetration across both the US, where Carevix™ achieved FDA clearance in 2023, and European markets with its CE-Marked approval. With more than 120 million women worldwide still subjected to outdated and painful procedures, Aspivix is steadfast in its commitment to modernizing gynecology. The funds will also support further clinical trials and post-market studies to solidify Carevix™’s standing as a superior alternative to conventional devices, ensuring that women globally receive care that truly respects their anatomical needs and comfort.
Aspivix’s vision is clear – every woman deserves a better, less painful experience during essential gynecologic procedures. This new funding round is not just an investment in technology, but an investment in a future where better, modern healthcare is accessible to every woman.
